Search Result

Results for "

VX

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Apolipoprotein (1) Apoptosis (3) Arenavirus (1) ATM/ATR (4) Aurora Kinase (3) Autophagy (20) Bacterial (1) Bcl-2 Family (1) Caspase (9) CFTR (28) Chloride Channel (2) Cholinesterase (ChE) (3) CXCR (1) Dengue Virus (1) DNA-PK (2) DNA/RNA Synthesis (5) Drug Intermediate (7) Drug Isomer (1) Drug Metabolite (2) ERK (2) Flavivirus (1) HBV (1) HCV (8) HCV Protease (4) HIV (11) HIV Protease (11) IMPDH (2) Influenza Virus (2) Isotope-Labeled Compounds (13) JAK (1) P-glycoprotein (2) p38 MAPK (5) PPAR (1) Reference Standards (13) SARS-CoV (8) Sigma Receptor (1) Sodium Channel (2) STING (2) TNF Receptor (1) VEGFR (1)
By Research Areas:	Cancer (28) Endocrinology (10) Infection (24) Inflammation/Immunology (24) Metabolic Disease (2) Neurological Disease (6)

By Targets:

Apolipoprotein (1)

Apoptosis (3)

Arenavirus (1)

ATM/ATR (4)

Aurora Kinase (3)

Autophagy (20)

Bacterial (1)

Bcl-2 Family (1)

Caspase (9)

CFTR (28)

Chloride Channel (2)

Cholinesterase (ChE) (3)

CXCR (1)

Dengue Virus (1)

DNA-PK (2)

DNA/RNA Synthesis (5)

Drug Intermediate (7)

Drug Isomer (1)

Drug Metabolite (2)

ERK (2)

Flavivirus (1)

HBV (1)

HCV (8)

HCV Protease (4)

HIV (11)

HIV Protease (11)

IMPDH (2)

Influenza Virus (2)

Isotope-Labeled Compounds (13)

JAK (1)

P-glycoprotein (2)

p38 MAPK (5)

PPAR (1)

Reference Standards (13)

SARS-CoV (8)

Sigma Receptor (1)

Sodium Channel (2)

STING (2)

TNF Receptor (1)

VEGFR (1)

By Research Areas:

Cancer (28)

Endocrinology (10)

Infection (24)

Inflammation/Immunology (24)

Metabolic Disease (2)

Neurological Disease (6)

Inhibitors & Agonists

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-13205

Belnacasan Maximum Cited Publications 169 Publications Verification VX-765	Caspase	Inflammation/Immunology
Belnacasan (VX-765) is an orally bioactive proagent of VRT-043198, which is a potent and selective inhibitor of IL-converting enzyme (ICE)/caspase-1 with K_is of 0.8 nM and less than 0.6 nM for caspase-1 and caspase-4, respectively. Belnacasan (VX-765) inhibits the release of LPS-induced IL-1β and IL-18 by human PBMCs with an IC₅₀ of ~0.7 μM .

HY-148800

Suzetrigine 5 Publications Verification VX-548	Sodium Channel	Neurological Disease
Suzetrigine (VX-548) is an orally active and highly selective Na_V1.8 inhibitor that acts as an analgesic. Suzetrigine is also a blocker of sodium channel protein type 10 subunit alpha. Suzetrigine is promising for research of acute pain after abdominoplasty and bunionectomy .

HY-13902

Berzosertib 20+ Cited Publications VE-822; VX-970; M6620	ATM/ATR Apoptosis STING Caspase	Infection Metabolic Disease Cancer
Berzosertib (VE-822) is an orally active, CNS-penetrant, and selective ATR kinase inhibitor. Berzosertib blocks ATR kinase activity, abrogates G₂/M cell cycle checkpoint, impairs DNA damage repair. Berzosertib induces apoptosis, inhibnits conlony migration, inhibits cell proliferation, and activates cGAS-STING axes in cancer cells. Berzosertib can be used for the research of cancers, such as head and neck squamous cell carcinoma, and colorectal cancer .

HY-13017

Ivacaftor 25+ Cited Publications VX-770	CFTR Autophagy	Endocrinology
Ivacaftor (VX-770) is a potent and orally bioavailable CFTR potentiator, targeting G551D-CFTR and F508del-CFTR with EC₅₀s of 100 nM and 25 nM, respectively.

HY-111772

Elexacaftor 45+ Cited Publications VX-445	CFTR Autophagy	Inflammation/Immunology
Elexacaftor (VX-445, Compound 1) is a modulator of cystic fibrosis transmembrane conductance regulator (CFTR). Elexacaftor (VX-445, Compound 1) facilitates the processing and trafficking of CFTR to increase the amount of CFTR at the cell surface .

HY-15448

Tezacaftor 20+ Cited Publications VX-661	CFTR	Cancer
Tezacaftor (VX-661) is a F508del CFTR corrector. It helps CFTR protein reach the cell surface. However, Ivacaftor (VX-770, HY-13017), a CFTR potentiator, helps to prolong the opening time of cell surface CFTR protein channels. Tezacaftor combining with Ivacaftor, shows potent efficacy against cystic fibrosis and diseases with homozygous for the CFTR Phe508del mutation. Moreover, Elexacaftor (VX-445, HY-111772) is also a CFTR corrector. Elexacaftor-Tezacaftor-Ivacaftor aims at with cystic fibrosis (CF) with at least one Phe508del mutation, often avoids the indication for lung transplantation .

HY-136270

Gartisertib 5 Publications Verification VX-803; M4344; ATR inhibitor 2	ATM/ATR	Cancer
Gartisertib (VX-803) is an ATP-competitive, orally active, and selective ATR inhibitor, with a K_i of <150 pM. Gartisertib potently inhibits ATR-driven phosphorylated checkpoint kinase-1 (Chk1) phosphorylation with an IC₅₀ of 8 nM. Antitumor activity .

HY-10328

Neflamapimod 5+ Cited Publications VX-745	p38 MAPK Autophagy	Inflammation/Immunology
Neflamapimod (VX-745) is a potent, blood-brain barrier penetrant, highly selective inhibitor of p38α inhibitor with an IC₅₀ for p38α of 10 nM and for p38β of 220 nM. Neflamapimod (VX-745) possesses anti-inflammatory activity.

HY-10161

Tozasertib 15+ Cited Publications VX 680; MK-0457	Aurora Kinase Autophagy	Cancer
Tozasertib (VX 680; MK-0457) is an inhibitor of Aurora A/B/C kinases with K_is of 0.6, 18, 4.6 nM, respectively.

HY-10235

Telaprevir 40+ Cited Publications VX-950	HCV Protease HCV SARS-CoV	Infection
Telaprevir (VX-950) is a highly selective, reversible, and potent peptidomimetic inhibitor of the HCV NS3-4A protease, the steady-state inhibitory constant (K_i) of Telaprevir is 7 nM against a genotype 1 (H strain) NS3 protease domain plus a NS4A cofactor peptide . Telaprevir inhibits SARS-CoV-2 3CL ^pro activity .

HY-13560

AVN-944 5 Publications Verification VX-944	Arenavirus DNA/RNA Synthesis Apoptosis Caspase Bcl-2 Family	Infection Cancer
AVN-944 (VX-944) is an orally active, potent, selective, noncompetitive and specific inhibitor of IMPDH (inosine monophosphate dehydrogenase). AVN-944 is an essential rate-limiting enzyme in de novo guanine nucleotide synthesis. AVN-944 is also an inhibitor of arenavirus RNA synthesis, and blocks arenavirus infection. AVN-944 has broad anti-cancer activities, and can be used for multiple myeloma (MM) and acute myeloid leukemia (AML) research .

HY-145603

Vanzacaftor 4 Publications Verification VX-121	CFTR Chloride Channel	Neurological Disease
Vanzacaftor (VX-121) is an orally active noval corrector of Cystic fibrosis transmembrane conductance regulator (CFTR). Vanzacaftor improves processing and trafficking of CFTR protein as well as increases chloride transport in triple combined with Tezacaftor (HY-15448) and Deutivacaftor. Vanzacaftor-Tezacaftor-Deutivacaftor is safe and well tolerated, improving lung function, respiratory symptoms, and CFTR function with cystic fibrosis, which is promising for research in the field of cystic fibrosis diseases .

HY-13262

Lumacaftor 15+ Cited Publications VX-809; VRT 826809	CFTR Autophagy	Inflammation/Immunology
Lumacaftor (VX-809; VRT 826809) is a CFTR modulator that corrects the folding and trafficking of CFTR protein.

HY-13252

MK-5108 5+ Cited Publications VX-689	Aurora Kinase Autophagy	Cancer
MK-5108 is a highly potent and specific inhibitor of Aurora A kinase with an IC₅₀ value of 0.064 nM.

HY-112226

VRT-043198 4 Publications Verification	Caspase Drug Metabolite	Inflammation/Immunology
VRT-043198, the agent metabolite of VX-765 (Belnacasan), is a potent, selective and blood-brain barrier permeable inhibitor of interleukin-converting enzyme/caspase-1 subfamily caspases. VRT-043198 exhibits K_i values of 0.8 nM and 0.6 nM for ICE/caspase-1 and caspase-4, respectively .

HY-10401

VX-702 4 Publications Verification	p38 MAPK Autophagy	Inflammation/Immunology
VX-702 is a highly selective inhibitor of p38α MAPK, 14-fold higher potency against the p38α versus p38β .

HY-13017S

Ivacaftor-d9 VX-770-d₉	CFTR	Cancer
Ivacaftor-d₉ is a potent CFTR modulator and exhibits an EC₅₀ value of 255 nM for CFTR potentiation in G551D/F508del HBE Cells. Ivacaftor-D9 acts as an orally active and improved deuterated Ivacaftor analog for cystic fibrosis research .

HY-19939S

VX-984 4 Publications Verification M9831	DNA-PK	Cancer
VX-984 is an orally active, potent, selective and BBB-penetrated DNA-PK inhibitor. VX-984 efficiently inhibits NHEJ (non-homologous end joining) and increases DSBs (DNA double-strand breaks). VX-984 can be used for glioblastomas (GBM) and non-small cell lung cancer (NSCLC) research. VX-984 is a de novo deuterium .

HY-14178

VX-11e 5+ Cited Publications	ERK	Cancer
VX-11e is a potent, selective, and orally bioavailable inhibitor of ERK with K_i < 2 nM.

HY-13986

Merimepodib 2 Publications Verification VX-497; MMPD	Flavivirus Dengue Virus HBV HCV	Infection Cancer
Merimepodib (VX-497) is a noncompetitive and oral inhibitor of inosine monophosphate dehydrogenase (IMPDH) with broad spectrum antiviral activities.

HY-78726

Fosamprenavir 4 Publications Verification Amprenavir phosphate; GW 433908	Drug Intermediate HIV HIV Protease	Infection
Fosamprenavir is an orally active inhibitor targeting HIV-1 protease and is a prodrug of Amprenavir (HY-17430). Fosamprenavir is hydrolyzed into Amprenavir (VX-478) by cell phosphatases in the intestinal epithelium. Amprenavir binds to the active site of HIV-1 protease, preventing the processing of viral gag and gag-pol polyprotein precursors, thereby inhibiting the formation of mature infectious virus particles and exerting anti-HIV-1 infection activity. Fosamprenavir can be used for the study of human immunodeficiency virus (HIV-1) infection .

HY-12353A

Pimodivir 5+ Cited Publications VX-787	Influenza Virus	Infection
Pimodivir (VX-787) is an orally bioavailable inhibitor of influenza A virus polymerases through interaction with the viral PB2 subunit.

HY-132820

Inaxaplin VX-147	Apolipoprotein	Others
Inaxaplin (VX-147) is an orally active apolipoprotein L1 (APOL1) function inhibitor (WO2020131807, compound 2). Inaxaplin can be used for the research of kidney disease .

HY-19676

Pralnacasan 1 Publications Verification VX-740; HMR 3480	Caspase	Inflammation/Immunology
Pralnacasan (VX-740) is a potent, selective, non-peptide and orally active interleukin-1β converting enzyme (ICE, caspase 1) inhibitor with a K_i of 1.4 nM. Pralnacasan inhibits proinflammatory cytokines IL-18, IL-1β , and IFN-γ. Pralnacasan has the potential for osteoarthritis and rheumatoid arthritis treatment .

HY-12469

Decernotinib 4 Publications Verification VX-509; VRT-831509	JAK	Inflammation/Immunology
Decernotinib is a potent, orally active JAK3 inhibitor, with K_is of 2.5, 11, 13 and 11 nM for JAK3, JAK1, JAK2, and TYK2, respectively.

HY-139346

VX-150 1 Publications Verification	Sodium Channel	Neurological Disease
VX-150 is an orally active, highly selective Na_V1.8 inhibitor. VX-150 has the potential for various pain indications research .

HY-P991567

VX5 VX5/5261	CXCR	Inflammation/Immunology Cancer
VX5 (VX5/5261) is a humanized IgG1κ monoclonal antibody inhibitor targeting BCA-1/CXCL13. VX5 significantly inhibits human CXCL13-mediated internalization of CXCR5, blocks both human and mouse CXCL13-dependent B-cells chemotaxis and migration. VX5 can be used to study autoimmune diseases like multiple sclerosis and arthritis, and cancers like gastric lymphomas and colon cancer .

HY-17430

Amprenavir 5+ Cited Publications VX-478	HIV HIV Protease SARS-CoV	Infection Cancer
Amprenavir (VX-478) is a HIV protease inhibitor (Ki=0.6 nM) used to treat HIV infection. Amprenavir is also a SARS-CoV 3CL ^pro inhibitor with an IC₅₀ of 1.09 μM.

HY-126394

Bamocaftor 1 Publications Verification VX-659	CFTR	Endocrinology
Bamocaftor (VX-659) is a cystic fibrosis transmembrane conductance regulator (CFTR) corrector designed to restore F508del-CFTR protein function. Bamocaftor can be used combine with Tezacaftor (HY-15448) and Ivacaftor (HY-13017) in cystic fibrosis research .

HY-145603A

(R)-Vanzacaftor 1 Publications Verification (R)-VX-121	CFTR	Inflammation/Immunology
(R)-Vanzacaftor ((R)-VX-121) is a Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) modulator with max activity of 30-60% and EC₅₀ <1 μM in enteroid cells. (R)-Vanzacaftor can be used for the research of cystic fibrosis .

HY-111772A

(R)-Elexacaftor (R)-VX-445	Drug Isomer CFTR	Inflammation/Immunology
(R)-Elexacaftor ((R)-VX-445) is the enantiomer of Elexacaftor (HY-111772). Elexacaftor is an orally active CFTR modulator that targets nucleotide-binding domain 1. Elexacaftor stabilizes misfolded F508del-CFTR protein, enhances its trafficking to the plasma membrane, and significantly improves metabolic stability, thermal stability and ion conductivity. Elexacaftor not only restores chloride transport function in nasal epithelial cells and rescues multiple CFTR mutation subtypes, but also exerts multiplicative synergistic effects with Ivacaftor (HY-13017), and is often used in a triple combination therapy with Tezacaftor (HY-15448). Elexacaftor is widely used in basic and clinical translational research on cystic fibrosis .

HY-17431

Fosamprenavir Calcium Salt 4 Publications Verification GW433908G	Drug Intermediate HIV HIV Protease	Infection
Fosamprenavir Calcium Salt (GW433908G) is an orally active inhibitor targeting HIV-1 protease and is a prodrug of Amprenavir (HY-17430). Fosamprenavir Calcium Salt is hydrolyzed into Amprenavir (VX-478) by cell phosphatases in the intestinal epithelium. Amprenavir binds to the active site of HIV-1 protease, preventing the processing of viral gag and gag-pol polyprotein precursors, thereby inhibiting the formation of mature infectious virus particles and exerting anti-HIV-1 infection activity. Fosamprenavir Calcium Salt can be used for the study of human immunodeficiency virus (HIV-1) infection .

HY-13574A

Biricodar 1 Publications Verification VX-710	P-glycoprotein	Cancer
Biricodar (VX-710) is a modulator of P-glycoprotein and MRP-1; shows effective chemosensitizing activity in multidrug resistant cells.

HY-75800

Lomibuvir 2 Publications Verification VX-222	DNA/RNA Synthesis HCV	Infection
Lomibuvir (VX-222), a selective, non-nucleoside polymerase inhibitor, targets thumb pocket 2 of the HCV NS5B polymerase (RdRp) with a K_d of 17 nM. Lomibuvir inhibits the 1b/Con1 HCV subgenomic replicon with an EC₅₀ of 5.2 nM. Lomibuvir preferentially inhibits elongative RNA synthesis rather than de novo-initiated RNA synthesis .

HY-13986A

(R)-Merimepodib (R)-VX-497; (R)-MMPD	IMPDH	Infection
(R)-Merimepodib is the isomer of Merimepodib (HY-13986), and can be used as an experimental control. Merimepodib (VX-497) is a noncompetitive and oral inhibitor of inosine monophosphate dehydrogenase (IMPDH) with broad spectrum antiviral activities.

HY-15448S

Tezacaftor-d4 VX-661-d₄	CFTR Autophagy	Cancer
Tezacaftor-d4 (VX-661-d4) is the deuterium-labeled Tezacaftor (HY-15448), a F508del CFTR corrector. Tezacaftor helps CFTR protein reach the cell surface .

HY-15448A

(Rac)-Tezacaftor (Rac)-VX-661	CFTR	Inflammation/Immunology
(Rac)-Tezacaftor ((Rac)-VX-661) is a racemate of Tezacaftor (HY-15448). Tezacaftor is a F508del CFTR corrector. (Rac)-Tezacaftor can be used for the research of cystic fibrosis .

HY-112267

Olacaftor VX-440	CFTR Autophagy	Inflammation/Immunology
Olacaftor (VX-440) is a cystic fibrosis transmembrane conductance regulator (CFTR) modulator extracted from patent US9782408.

HY-13017S2

Ivacaftor-d18 VX-770-d₁₈	Autophagy CFTR	Endocrinology
Ivacaftor-d₁₈ is the deuterium labeled Ivacaftor . Ivacaftor (VX-770) is a potent and orally bioavailable CFTR potentiator, targeting G551D-CFTR and F508del-CFTR with EC₅₀s of 100 nM and 25 nM, respectively .

HY-111772S1

Elexacaftor-d3 VX-445-d₃	Isotope-Labeled Compounds	Inflammation/Immunology
Elexacaftor-d3 (VX-445-d3) is the deuterium labeled Elexacaftor (HY-111772) .

HY-13017S3

Ivacaftor-d4 VX-770-d₄	CFTR	Endocrinology
Ivacaftor-d4 (VX-770-d4) is the deuterium labeled-Ivacaftor (HY-13017). Ivacaftor is a potent and orally active CFTR potentiator, targeting G551D-CFTR and F508del-CFTR with EC₅₀s of 100 nM and 25 nM, respectively .

HY-13262S

Lumacaftor-d4 VX-809-d₄; VRT 826809-d₄	Isotope-Labeled Compounds	Others
Lumacaftor-d₄ is the deuterium labeled Lumacaftor (HY-13262) .

HY-19939S2

(R)-VX-984 (R)-M9831	DNA-PK	Others
(R)-VX-984 ((R)-M9831) is the (R)-enantiomer of VX-984. VX-984 is a potent DNA-PK inhibitor.

HY-145603S

Vanzacaftor-d4 VX-121-d₄	Isotope-Labeled Compounds CFTR Chloride Channel	Neurological Disease
Vanzacaftor-d₄ (VX-121-d₄) is the deuterium labeled Vanzacaftor (HY-145603). Vanzacaftor is an orally active noval corrector of Cystic fibrosis transmembrane conductance regulator (CFTR). Vanzacaftor improves processing and trafficking of CFTR protein as well as increases chloride transport in triple combined with Tezacaftor (HY-15448) and Deutivacaftor. Vanzacaftor-Tezacaftor-Deutivacaftor is safe and well tolerated, improving lung function, respiratory symptoms, and CFTR function with cystic fibrosis, which is promising for research in the field of cystic fibrosis diseases .

HY-10401R

VX-702 (Standard)	Reference Standards p38 MAPK Autophagy	Inflammation/Immunology
VX-702 (Standard) is the analytical standard of VX-702. This product is intended for research and analytical applications. VX-702 is a highly selective inhibitor of p38α MAPK, 14-fold higher potency against the p38α versus p38β .

HY-118917

VX-148	IMPDH	Inflammation/Immunology
VX-148 is an orally active immunosuppressant, which is a non-competitive inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor with K_i values for IMPDH Ⅱ and IMPDH Ⅰ of 6 and 14 nM respectively. VX-148 can significantly inhibit the proliferation of human peripheral blood mononuclear cells (PBMC) stimulated by T-cell mitogen (PHA) or B-cell mitogen (SPAS). VX-148 has high selectivity for lymphocytes (such as L1210, Jurkat T cells, and Raji B cells), but has no significant toxicity to non-lymphoid cells. VX-148 can inhibit antibody responses in mouse models and significantly prolong the survival time of transplanted skin in allogeneic skin transplantation models. VX-148 can be used in the research of autoimmune diseases (such as rheumatoid arthritis, psoriasis) and organ transplantation anti-rejection .

HY-13017B

Ivacaftor hydrate VX-770 hydrate	CFTR Autophagy	Endocrinology
Ivacaftor hydrate (VX-770 hydrate) is an orally bioavailable CFTR potentiator, used for cystic fibrosis treatment.

HY-13205R

Belnacasan (Standard) VX-765 (Standard)	Caspase Reference Standards	Inflammation/Immunology
Belnacasan (Standard) is the analytical standard of Belnacasan. This product is intended for research and analytical applications. Belnacasan (VX-765) is an orally bioactive proagent of VRT-043198, which is a potent and selective inhibitor of IL-converting enzyme (ICE)/caspase-1 with Kis of 0.8 nM and less than 0.6 nM for caspase-1 and caspase-4, respectively. Belnacasan (VX-765) inhibits the release of LPS-induced IL-1β and IL-18 by human PBMCs with an IC50 of ~0.7 μM .

HY-112267A

(R)-Olacaftor (R)-VX-440	CFTR	Others
(R)-Olacaftor ((R)-VX-440) is a Cystic fibrosis transmembrane conductance regulator (CFTR) modulator. (R)-Olacaftor has good potential for the study of cystic fibrosis (CF) .

HY-77931

(R)-1-[5-Amino-2-(2-benzyloxy-1,1-dimethyl-ethyl)-6-fluoro-indol-1-yl]-3-benzyloxy-propan-2-ol VX-661 intermediate	Drug Intermediate	Others
(R)-1-[5-Amino-2-(2-benzyloxy-1,1-dimethyl-ethyl)-6-fluoro-indol-1-yl]-3-benzyloxy-propan-2-ol (VX-661 intermediate) is a drug intermediate for synthesis of various active compounds.

Cat. No.	Product Name	Target	Research Area	Image

HY-P99407

Pepinemab 3 Publications Verification VX 15/2503	Inhibitory Antibodies	Neurological Disease Cancer
Pepinemab (VX 15/2503) is a human monoclonal antibody against SEMA4D, a signalling protein 4D (SEMA4D), also known as CD100, which is a regulator of neuronal development and plays a role in a variety of cellular processes. Pepinemab can be used in the study of various neurodegenerative diseases such as Alzheimer's disease by blocking the activity of SEMA4D .

HY-P991567

VX5 VX5/5261	CXCR	Inflammation/Immunology Cancer
VX5 (VX5/5261) is a humanized IgG1κ monoclonal antibody inhibitor targeting BCA-1/CXCL13. VX5 significantly inhibits human CXCL13-mediated internalization of CXCR5, blocks both human and mouse CXCL13-dependent B-cells chemotaxis and migration. VX5 can be used to study autoimmune diseases like multiple sclerosis and arthritis, and cancers like gastric lymphomas and colon cancer .

HY-P991625

VX70	VEGFR	Cancer
VX70 is a humanized monoclonal antibody inhibitor targeting VEGF-A. VX70 can be used for cancers research .

HY-P991554

FFP-104	TNF Receptor	Inflammation/Immunology
FFP-104 is a humanized IgG4 monoclonal antibody inhibitor targeting TNFRSF5/CD40. VX70 can be used for chronic autoimmune liver diseases research, such as primary biliary cholangitis (PBC) .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-78726

Fosamprenavir 4 Publications Verification Amprenavir phosphate; GW 433908	Infection Natural Products Classification of Application Fields Endogenous metabolite Disease Research Fields Source Classification	Drug Intermediate HIV HIV Protease
Fosamprenavir is an orally active inhibitor targeting HIV-1 protease and is a prodrug of Amprenavir (HY-17430). Fosamprenavir is hydrolyzed into Amprenavir (VX-478) by cell phosphatases in the intestinal epithelium. Amprenavir binds to the active site of HIV-1 protease, preventing the processing of viral gag and gag-pol polyprotein precursors, thereby inhibiting the formation of mature infectious virus particles and exerting anti-HIV-1 infection activity. Fosamprenavir can be used for the study of human immunodeficiency virus (HIV-1) infection .

HY-17431

Fosamprenavir Calcium Salt 4 Publications Verification GW433908G	Infection Natural Products Classification of Application Fields Endogenous metabolite Disease Research Fields Source Classification	Drug Intermediate HIV HIV Protease
Fosamprenavir Calcium Salt (GW433908G) is an orally active inhibitor targeting HIV-1 protease and is a prodrug of Amprenavir (HY-17430). Fosamprenavir Calcium Salt is hydrolyzed into Amprenavir (VX-478) by cell phosphatases in the intestinal epithelium. Amprenavir binds to the active site of HIV-1 protease, preventing the processing of viral gag and gag-pol polyprotein precursors, thereby inhibiting the formation of mature infectious virus particles and exerting anti-HIV-1 infection activity. Fosamprenavir Calcium Salt can be used for the study of human immunodeficiency virus (HIV-1) infection .

HY-17431R

Fosamprenavir Calcium Salt (Standard) GW433908G (Standard)	Structural Classification Natural Products Endogenous metabolite Source Classification	Reference Standards Drug Intermediate HIV HIV Protease
Fosamprenavir Calcium Salt (GW433908G) (Standard) is the analytical standard of Fosamprenavir Calcium Salt (HY-17431R). This product is intended for research and analytical applications. Fosamprenavir Calcium Salt (GW433908G) is an orally active inhibitor targeting HIV-1 protease and is a prodrug of Amprenavir (HY-17430). Fosamprenavir Calcium Salt is hydrolyzed into Amprenavir (VX-478) by cell phosphatases in the intestinal epithelium. Amprenavir binds to the active site of HIV-1 protease, preventing the processing of viral gag and gag-pol polyprotein precursors, thereby inhibiting the formation of mature infectious virus particles and exerting anti-HIV-1 infection activity. Fosamprenavir Calcium Salt can be used for the study of human immunodeficiency virus (HIV-1) infection .

Cat. No.	Product Name	Chemical Structure

HY-13017S

Ivacaftor-d9
Ivacaftor-d₉ is a potent CFTR modulator and exhibits an EC₅₀ value of 255 nM for CFTR potentiation in G551D/F508del HBE Cells. Ivacaftor-D9 acts as an orally active and improved deuterated Ivacaftor analog for cystic fibrosis research .

HY-19939S

VX-984 4 Publications Verification
VX-984 is an orally active, potent, selective and BBB-penetrated DNA-PK inhibitor. VX-984 efficiently inhibits NHEJ (non-homologous end joining) and increases DSBs (DNA double-strand breaks). VX-984 can be used for glioblastomas (GBM) and non-small cell lung cancer (NSCLC) research. VX-984 is a de novo deuterium .

HY-15448S

Tezacaftor-d4
Tezacaftor-d4 (VX-661-d4) is the deuterium-labeled Tezacaftor (HY-15448), a F508del CFTR corrector. Tezacaftor helps CFTR protein reach the cell surface .

HY-13017S2

Ivacaftor-d18
Ivacaftor-d₁₈ is the deuterium labeled Ivacaftor . Ivacaftor (VX-770) is a potent and orally bioavailable CFTR potentiator, targeting G551D-CFTR and F508del-CFTR with EC₅₀s of 100 nM and 25 nM, respectively .

HY-111772S1

Elexacaftor-d3
Elexacaftor-d3 (VX-445-d3) is the deuterium labeled Elexacaftor (HY-111772) .

HY-13017S3

Ivacaftor-d4
Ivacaftor-d4 (VX-770-d4) is the deuterium labeled-Ivacaftor (HY-13017). Ivacaftor is a potent and orally active CFTR potentiator, targeting G551D-CFTR and F508del-CFTR with EC₅₀s of 100 nM and 25 nM, respectively .

HY-13262S

Lumacaftor-d4
Lumacaftor-d₄ is the deuterium labeled Lumacaftor (HY-13262) .

HY-19939S2

(R)-VX-984
(R)-VX-984 ((R)-M9831) is the (R)-enantiomer of VX-984. VX-984 is a potent DNA-PK inhibitor.

HY-145603S

Vanzacaftor-d4

Vanzacaftor-d₄ (VX-121-d₄) is the deuterium labeled Vanzacaftor (HY-145603). Vanzacaftor is an orally active noval corrector of Cystic fibrosis transmembrane conductance regulator (CFTR). Vanzacaftor improves processing and trafficking of CFTR protein as well as increases chloride transport in triple combined with Tezacaftor (HY-15448) and Deutivacaftor. Vanzacaftor-Tezacaftor-Deutivacaftor is safe and well tolerated, improving lung function, respiratory symptoms, and CFTR function with cystic fibrosis, which is promising for research in the field of cystic fibrosis diseases .

HY-78726S

Fosamprenavir-d4

Fosamprenavir-d₄ is the Deuterium-labeled Fosamprenavir (HY-78726). Fosamprenavir is an orally active inhibitor targeting HIV-1 protease and is a prodrug of Amprenavir (HY-17430). Fosamprenavir is hydrolyzed into Amprenavir (VX-478) by cell phosphatases in the intestinal epithelium. Amprenavir binds to the active site of HIV-1 protease, preventing the processing of viral gag and gag-pol polyprotein precursors, thereby inhibiting the formation of mature infectious virus particles and exerting anti-HIV-1 infection activity. Fosamprenavir can be used for the study of human immunodeficiency virus (HIV-1) infection .

HY-10235S

Telaprevir-d4
Telaprevir-d₄ is the deuterium labeled Telaprevir. Telaprevir (VX-950) is a highly selective, reversible, and potent peptidomimetic inhibitor of the HCV NS3-4A protease, the steady-state inhibitory constant (Ki) of Telaprevir is 7 nM against a genotype 1 (H strain) NS3 protease domain plus a NS4A cofactor peptide . Telaprevir inhibits SARS-CoV-2 3CLpro activity .

HY-13017S1

Ivacaftor-d19
Ivacaftor-d₉ is a potent CFTR modulator and exhibits an EC₅₀ value of 255 nM for CFTR potentiation in G551D/F508del HBE Cells. Ivacaftor-D9 acts as an orally active and improved deuterated Ivacaftor analog for cystic fibrosis research .

HY-15448S1

Tezacaftor-d6

Tezacaftor-d₆ (VX-661-d₆) is deuterium labeled Tezacaftor. Tezacaftor (VX-661) is a F508del CFTR corrector. It helps CFTR protein reach the cell surface. However, Ivacaftor (VX-770, HY-13017), a CFTR potentiator, helps to prolong the opening time of cell surface CFTR protein channels. Tezacaftor combining with Ivacaftor, shows potent efficacy against cystic fibrosis and diseases with homozygous for the CFTR Phe508del mutation. Moreover, Elexacaftor (VX-445, HY-111772) is also a CFTR corrector. Elexacaftor-Tezacaftor-Ivacaftor aims at with cystic fibrosis (CF) with at least one Phe508del mutation, often avoids the indication for lung transplantation .

HY-17430S2

Amprenavir-13C6
Amprenavir- ¹³C₆ (VX-478- ¹³C₆) is ¹³C labeled Amprenavir. Amprenavir (VX-478) is a HIV protease inhibitor (Ki=0.6 nM) used to treat HIV infection. Amprenavir is also a SARS-CoV 3CL ^pro inhibitor with an IC₅₀ of 1.09 μM.

HY-13017S4

Ivacaftor-13C6
Ivacaftor- ¹³C₆ (VX-770- ¹³C₆) is ¹³C labeled Ivacaftor. Ivacaftor (VX-770) is a potent and orally bioavailable CFTR potentiator, targeting G551D-CFTR and F508del-CFTR with EC₅₀s of 100 nM and 25 nM, respectively.

HY-17430S1

Amprenavir-d4-1
Amprenavir-d₄-1 is deuterium labeled Amprenavir. Amprenavir (VX-478) is a HIV protease inhibitor (Ki=0.6 nM) used to treat HIV infection. Amprenavir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 1.09 μM.

HY-17430S

Amprenavir-d4
Amprenavir-d₄ is the deuterium labeled Amprenavir. Amprenavir (VX-478) is a HIV protease inhibitor (Ki=0.6 nM) used to treat HIV infection. Amprenavir is also a SARS-CoV 3CLpro inhibitor with an IC₅₀ of 1.09 μM .

HY-78726S2

Fosamprenavir-13C6

Fosamprenavir- ¹³C₆ is the ¹³C-labeled Fosamprenavir (HY-78726). Fosamprenavir is an orally active inhibitor targeting HIV-1 protease and is a prodrug of Amprenavir (HY-17430). Fosamprenavir is hydrolyzed into Amprenavir (VX-478) by cell phosphatases in the intestinal epithelium. Amprenavir binds to the active site of HIV-1 protease, preventing the processing of viral gag and gag-pol polyprotein precursors, thereby inhibiting the formation of mature infectious virus particles and exerting anti-HIV-1 infection activity. Fosamprenavir can be used for the study of human immunodeficiency virus (HIV-1) infection .

HY-111772S

Elexacaftor-13C,d3
Elexacaftor- ¹³C,d₃ is the deuterium labeled Elexacaftor (HY-111772) .

HY-136270S

Gartisertib-d8
Gartisertib-d₈ (VX-803-d₈) is the deuterium labeled Gartisertib (HY-136270). Gartisertib (VX-803) is an ATP-competitive, orally active, and selective ATR inhibitor, with a K_i of <150 pM. Gartisertib potently inhibits ATR-driven phosphorylated checkpoint kinase-1 (Chk1) phosphorylation with an IC₅₀ of 8 nM. Antitumor activity .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks